DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Angiomax (Bivalirudin) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Bleeding

In 6010 patients undergoing PCI treated in the REPLACE-2 trial, Angiomax patients exhibited statistically significantly lower rates of bleeding, transfusions, and thrombocytopenia as noted in Table 2.

Table 2. Major Hematologic Outcomes REPLACE-2 Study (Safety Population)
1 GPIs were administered to 7.2% of patients in the Angiomax with provisional GPI group
2 Defined as the occurence of any of the following: intracranial bleeding, retroperitoneal bleeding, a transfusion of ≥2 units of blood/blood products, a fall in hemoglobin >4 g/dL, whether of not bleeding site is identified, spontaneous or non-spontaneous blood loss with a decrease in hemoglobin >3 g/dL
3 Defined as observed bleeding that does not meet the criteria for major hemorrhage
4 TIMI major bleeding is defined as intracranial, or a fall in adjusted Hgb >5 g/dL or Hct of >15%: TIMI minor bleeding is defined as a fall in adjusted Hgb of 3 to <5 g/dL or a fall in adjusted Hct of 9 to <15%, with a bleeding site such as hematuria, hematemesis, hematomas, retroperitoneal bleeding or a decrease in Hgb of >4 g/dL with no bleeding site
5 If <100,000 and >25% reduction from baseline, or <50,000
Angiomax with "provisional" GPI1
n=2914
HEPARIN + GPI
(n=2987)
p-value
Protocol defined major hemorrhage2 (%) 2.3% 4.0% <0.001
Protocol defined minor hemorrhage3 (%) 13.6% 25.8% <0.001
TIMI defined bleeding4
  - Major 0.6% 0.9% 0.259
  - Minor 1.3% 2.9 <0.001
Non-access site bleeding
  - Retroperitoneal bleeding 0.2% 0.5% 0.069
  - Intracranial bleeding <0.1% 0.1% 1.0
Access site bleeding
  - Sheath site bleeding 0.9% 2.4% <0.001
Thrombocytopenia5
  <100,000 0.7% 1.7% <0.001
  <50,000 0.3% 0.6% 0.039
Transfusions
  - RBC 1.3% 1.9% 0.08
  - Platelets 0.3% 0.6% 0.095

In 4312 patients undergoing PTCA for treatment of unstable angina in 2 randomized, double-blind studies comparing Angiomax to heparin, Angiomax patients exhibited lower rates of major bleeding and lower requirements for blood transfusions. The incidence of major bleeding is presented in Table 3. The incidence of major bleeding was lower in the Angiomax group than in the heparin group.

Table 3. Major Bleeding and Transfusions in BAT Trial (all patients)1
1 No monitoring of ACT (or PTT) was done after a target ACT was achieved.
2 Major hemorrhage was defined as the occurence of any of the following, intracranial bleeding, retroperitoneal bleeding, clinically overt bleeding with a decrease in hemoglobin ≥3 g/dL or leading to a transfusion of ≥2 units of blood. This table includes data from the entire hospitalization period.
Angiomax
N=2161
Heparin
N=2151
No. (%) Patients with Major hemorrhage2 79 (3.7) 199 (9.3)
  - with ≥3 g/dL fall in Hgb 41 (1.9) 124 (5.8)
  - with ≥5 g/dL fall in Hgb 14 (0.6) 47 (2.2)
  - retroperitoneal bleeding 5 (0.2) 15 (0.7)
  - intracranial bleeding 1 (<0.1) 2 (0.1)
  - Required transfusions 43 (2.0) 123 (5.7)

In the AT-BAT study, of the 51 patients with HIT/HITTS, 1 patient who did not undergo PCI had major bleeding during CABG on the day following angiography. Nine patients had minor bleeding (mostly due to access site bleeding), and 2 patients developed thrombocytopenia.

Other Adverse Reactions

Adverse reactions, other than bleeding, observed in clinical trials were similar between the Angiomax treated patients and the control groups.

Adverse reactions (related adverse events) seen in clinical studies in patients undergoing PCI and PTCA are shown in Tables 4 and 5.

Table 4. Most frequent (≥0.2%) treatment-related adverse events (reactions) (through 30 days) in the REPLACE-2 Safety population
Note: A patient could have more than one event in any category.
Abbreviation: AE = adverse event.
Angiomax with
"provisional"
GPI1
(N = 2914)

Heparin+GPI
(N = 2987)
n    (%) n    (%)
Patients with at least one treatment-related AE 78    (2.7) 115    (3.9)
 
Thrombocytopenia 9    (0.3) 30    (1.0)
Nausea 15    (0.5) 7    (0.2)
Hypotension 7    (0.2) 11    (0.4)
Angina pectoris 5    (0.2) 12    (0.4)
Headache 6    (0.2) 5    (0.2)
Injection site pain 3    (0.1) 8    (0.3)
Nausea and vomiting 2    (0.1) 6    (0.2)
Vomiting 3    (0.1) 5    (0.2)

Table 5. Adverse Events Other Than Bleeding Occurring In ≥5% Of Patients In Either Treatment Group In BAT Trial
  Treatment Group
EVENT ANGIOMAX
N=2161
HEPARIN
N=2151
Number of Patients (%)
CARDIOVASCULAR
    Hypotension 262 (12) 371 (17)
    Hypertension 135 (6) 115 (5)
    Bradycardia 118 (5) 164 (8)
GASTROINTESTINAL
    Nausea 318 (15) 347 (16)
    Vomiting 138 (6) 169 (8)
    Dyspepsia 100 (5) 111 (5)
GENITOURINARY
    Urinary retention 89 (4) 98 (5)
MISCELLANEOUS
    Back pain 916 (42) 944 (44)
    Pain 330 (15) 358 (17)
    Headache 264 (12) 225 (10)
    Injection site pain 174 (8) 274 (13)
    Insomnia 142 (7) 139 (6)
    Pelvic pain 130 (6) 169 (8)
    Anxiety 127 (6) 140 (7)
    Abdominal pain 103 (5) 104 (5)
    Fever 103 (5) 108 (5)
    Nervousness 102 (5) 87 (4)

Serious, non-bleeding adverse events were experienced in 2% of 2161 Angiomax-treated patients and 2% of 2151 heparin-treated patients. The following individual serious non-bleeding adverse events were rare (>0.1% to <1%) and similar in incidence between Angiomax- and heparin-treated patients. These events are listed by body system: Body as a Whole:  fever, infection, sepsis; Cardiovascular:  hypotension, syncope, vascular anomaly, ventricular fibrillation; Nervous:  cerebral ischemia, confusion, facial paralysis; Respiratory:  lung edema; Urogenital:  kidney failure, oliguria. In the BAT trial, there was no causality assessment for adverse events.

Immunogenicity/Re-Exposure

In in vitro studies, Angiomax exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS.

Among 494 subjects who received Angiomax in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests. Neither subject demonstrated clinical evidence of allergic or anaphylactic reactions and repeat testing was not performed. Nine additional patients who had initial positive tests were negative on repeat testing.

Postmarketing Experience

Because postmarketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following adverse reactions have been identified during postapproval use of Angiomax: fatal bleeding; hypersensitivity and allergic reactions including reports of anaphylaxis; lack of anticoagulant effect; thrombus formation during PCI with and without intracoronary brachytherapy, including reports of fatal outcomes.



REPORTS OF SUSPECTED ANGIOMAX SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Angiomax. The information is not vetted and should not be considered as verified clinical evidence.

Possible Angiomax side effects / adverse reactions in 55 year old male

Reported by a physician from United States on 2011-10-18

Patient: 55 year old male weighing 95.0 kg (209.0 pounds)

Reactions: Medical Device Complication, Surgical Procedure Repeated, Incorrect Drug Administration Duration, Coronary Artery Thrombosis, NO Therapeutic Response, Coagulation Time Abnormal, Myocardial Infarction

Adverse event resulted in: death

Suspect drug(s):
Angiomax

Other drugs received by patient: Plavix; Integrilin



Possible Angiomax side effects / adverse reactions in 74 year old male

Reported by a individual with unspecified qualification from Spain on 2011-10-20

Patient: 74 year old male

Reactions: Anaemia, Coagulopathy

Suspect drug(s):
Aspirin
    Dosage: 100 mg
    Indication: Acute Coronary Syndrome
    Start date: 2011-05-11
    End date: 2011-05-11

Angiomax
    Dosage: 250 mg, intravenous
    Start date: 2011-05-11
    End date: 2011-05-11

Arixtra
    Dosage: 2.5 mg, qd, subcutaneous
    Start date: 2011-05-11
    End date: 2011-05-11

Plavix
    Dosage: 300 mg, qd, oral
    Administration route: Oral
    Indication: Acute Coronary Syndrome
    Start date: 2011-05-11
    End date: 2011-05-11

Other drugs received by patient: Pantoprazole



Possible Angiomax side effects / adverse reactions in 80 year old male

Reported by a physician from United Kingdom on 2011-11-02

Patient: 80 year old male

Reactions: Death

Adverse event resulted in: death

Suspect drug(s):
Angiomax

Other drugs received by patient: Aspirin; Clopidogrel



See index of all Angiomax side effect reports >>

Drug label data at the top of this Page last updated: 2013-05-15

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017